Prognostic and predictive values of a multimodal nomogram incorporating tumor and peritumor morphology with immune status in resectable lung adenocarcinoma.

J Immunother Cancer · 2025 · PMC11887283 · PMID 40050046

Europe PMC DOI

hedged sentences

0.1170

closest p · 2.3× alpha

0.1170

boldest claim

The sentences

did not reach statistical significancep=0.117not close (p > 0.1)

However, the association between immune score and DFS did not reach statistical significance in the immune-excluded phenotype (HR=2.29, 95% CI 0.81 to 6.49, p=0.117) or the inflamed phenotype (HR=1.21, 95% CI 0.67 to 2.17, p=0.535).

also in 111,027 other papers

showed a trendno p-value reported

In this subgroup, patients with a benefit rate of ≤10% had longer DFS without adjuvant chemotherapy (HR=2.05, 95% CI 1.50 to 2.80, p<0.001, figure 4F ), while those with a benefit rate of >10% and ≤25% showed a trend of prolonged DFS with adjuvant chemotherapy, although not significant (HR=1.06, 95% CI 0.49 to 2.80, p=0.883, figure 4G ), suggesting that the adjuvant chemotherapy benefit rate may support individualized treatment decisions for candidates for adjuvant chemotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.